 |
[email protected] |
 |
3275638434 |
 |
 |
| Paper Publishing WeChat |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Xinyu Yu
Full-Text PDF
XML 664 Views
DOI:10.17265/1548-6648/2022.02.004
School of Biological Science, University of California, Irvine, Irvine, California, 92697, USA
NDM (neonatal diabetes mellitus) is a rare genetic disease, which happens in the 6 months of life. Some patients with NDM heal on their own, but the other patients will show the symptoms of NDM for their whole life. Based on the presence of the remission phase, NDM is divided into two categories: TNDM (transient neonatal diabetes mellitus) and PNDM (permanent neonatal diabetes mellitus). As a genetic disease, the mutations in different genes lead to different symptoms and the presence of the remission phase. The mutation in INS gene will cause PNDM, and the mutations on KCNJ11 and ABCC8 genes and the abnormalities of chromosome 6q24 will lead to TNDM. Previous articles have always given information about diseases rather scatteredly: they only studied only mutated gene in an article. Unlike them, this article will discuss and analyze these three types of mutation and both PNDM and TNDM in one article. It will give the pathologic mechanism of the diseases, and, for different mutated genes, three treatments are given in this article at the same time. The compilation shows more clearly about the different symptoms corresponding to the different mutated genes and the mechanism of the disease.
NDM, genetic mutations, insulin, sulfonylurea, CRISPR/CAS9.
Journal of US-China Medical Science 19 (2022) 70-76
[1] Walker, H. K., Hall, W. D., and Hurst, J. W. 1990. Clinical Methods: The History, Physical, and Laboratory Examinations. Oxford: Butterworth-Heinemann Book.
[2] Wilcox, G. 2005. “Insulin and Insulin Resistance.” The Clinical biochemist Reviews 26 (2): 19-39.
[3] Grunberger, G., and Zick, Y. 2002. Insulin Signaling: From Cultured Cells to Animal Models. Cleveland: CRC Press.
[4] American Diabetes Association. 2018. “Economic Costs of Diabetes in the U.S. in 2017.” Diabetes Care 41 (5): 917-28.
[5] Centers for Disease Control and Prevention. 2020. “What Is Diabetes?” Accessed June 11, 2020. https://www.cdc.gov/diabetes/basics/diabetes.html.
[6] Atkinson, M. A., Eisenbarth, G. S., and Michels, A. W. 2014. “Type 1 Diabetes.” Lancet 383 (9911): 69-82.
[7] Haller, M. J., Atkinson, M. A., and Schatz, D. 2006. “Type 1 Diabetes Mellitus: Etiology, Presentation, and Management.” Pediatric Clinics of North America 52 (6): 1553-78.
[8] Swansea, R. W. 2019. IDF Diabetes Atlas 9th Edition 2019. https://diabetesatlas.org/en/.
[9] Chatterjee, S., Khunti, K., and Davies, M. J 2017. “Type 2 Diabetes.” The Lancet 389 (10085): 2239-51.
[10] Vijan, S. 2010. “Type 2 Diabetes.” Annals of Internal Medicine 152 (5): ITC3-1.
[11] Buchanan, T. A., and Xiang, A. H. 2005. “Gestational Diabetes Mellitus.” Acta Medica Austriaca 31 (3): 485-91.
[12] Polak, M., and Cavé, H. 2007. “Neonatal Diabetes Mellitus: A Disease Linked to Multiple Mechanisms.” Orphanet Journal of Rare Diseases 2 (1): 12.
[13] Pinney, Sara E, and Jennifer A Sutter. “Neonatal Diabetes Mellitus.” Up To Date, 24 Mar. 2020, https://www.uptodate.com/contents/neonatal-diabetes-mellitus?search=neonatal+diabetes+mellitus&source=search_result&selectedTitle=1~16&usage_type=default&display_rank=1#H3215906073.”
[14] Aguilar-Bryan, L., and Bryan. J. 2008. “Neonatal Diabetes Mellitus.” Endocrine Reviews 29 (3): 265-91.
[15] Fosel, S. 1995. “Transient and Permanent Neonatal Diabetes.” European Journal of Pediatrics 154 (12): 944-8.
[16] Temple, I. K. 2002. “Transient Neonatal Diabetes, A Disorder of Imprinting.” Journal of Medical Genetics 39 (12): 872.
[17] Lemelman, M. B., Letourneau, L., and Greeley, S. A. W. 2018. “Neonatal Diabetes Mellitus: An Update on Diagnosis and Management.” Clinics in Perinatology 45 (1): 41-59.
[18] Rubio-Cabezas, O., Klupa, T., and Malecki, M. J. 2011. “Permanent Neonatal Diabetes Mellitus—The Importance of Diabetes Differential Diagnosis in Neonates and Infants.” European Journal of Clinical Investigation 41 (3): 323-33.
[19] Beltrand, J., et al. 2015. “Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients with Neonatal Diabetes Owing to Potassium Channel Mutations.” Diabetes Care 38 (11): 2033-41.
[20] Babenko, A. P., Aguilar-Bryan, L., and Bryan, J. 1998. “A View of SUR/KIR6.X, KATP channels.” Annual Review of Physiology 60 (1): 667-87.
[21] Nichols, C. G. 2006. “KATP Channels as Molecular Sensors of Cellular Metabolism.” Nature 440 (7083): 470-6.
[22] Franco, E. D., et al. 2020. “Update of Variants Identified in the Pancreatic Beta Cell K ATP Channel Genes KCNJ11 and ABCC8 in Individuals with Congenital Hyperinsulinism and Diabetes.” Human Mutation 41 (2): 884-905.
[23] Liu, M., Sun, J. H., Cui, J. Q., Chen, W., Guo, H., Barbetti, F., and Arvan, P. 2015. “INS-Gene Mutations: From Genetics and Beta Cell Biology to Clinical Disease.” Mol Aspects Med. 42: 3-18.
[24] Garin, I., et al. 2010. “Recessive Mutations in the INS Gene Result in Neonatal Diabetes through Reduced Insulin Biosynthesis.” Proceedings of the National Academy of Sciences of the United States of America 107 (7): 3105-10.
[25] Yorifuji, T., Higuchi, S., Hosokawa, Y., and Kawakita, R. 2018. “Chromosome 6q24-Related Diabetes Mellitus.” Clinical Pediatric Endocrinology 27 (2): 59-65.
[26] Mackay, D. J. G., and Temple, I. K. 2010. “Transient Neonatal Diabetes Mellitus Type 1.” American Journal of Medical Genetics Part C: Seminars in Medical Genetics 154 (3).
[27] Abramowicz, M. J., Andrien, M., Dupont, E., Dorchy, H., Parma, J., Duprez, L., Ledley, F. D., Courtens, W., and Vamos, E 1994. “Isodisomy of Chromosome 6 in a Newborn with Methylmalonic Acidemia and Agenesis of Pancreatic Beta Cells Causing Diabetes Mellitus.” Journal of Clinical Investigation 94 (1): 418-21.
[28] Flanagan, S. E., Patch, A. M., Mackay, D. J. G., Edghill, E. L., Gloyn, A. L., Robinson, D., Shield, J. P. H., Temple, K., Ellard, S., and Hattersley, A. T. 2007. “Mutations in ATP-Sensitive K+ Channel Genes Cause Transient Neonatal Diabetes and Permanent Diabetes in Childhood or Adulthood.” Diabetes 56 (7): 1930-7.
[29] Pearson, E. R., et al. 2006. “Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes due to Kir6.2 Mutations.” New England Journal of Medicine 355 (5): 467-77.
[30] Jiang, F., and Doudna, J. A. 2020. “CRISPR-Cas9 Structures and Mechanisms.” Annual Review of Biophysics 46 (1): 505-29.
[31] Li, Y., Glass, Z., Huang, M., Chen, Z., and Xu, Q. 2020. “Ex vivo Cell-Based CRISPR/Cas9 Genome Editing for Therapeutic Applications.” Biomaterials 234: 119711.
[32] Krentz, N., and Lynn, F. C. 2016. Using CRISPR-Cas9 Genome Editing to Enhance Cell Based Therapies for the Treatment of Diabetes Mellitus. New York: Springer.